Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 18/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512001 | 0.90 | CES2 (0.39) | CES2CES1GPR6 | |
| SCHEMBL20512002 | 0.83 | CES2 (0.40) | CES2CES1 | |
| SCHEMBL20164104 | 0.83 | CES2 (0.38) | CES2CES1 | |
| SCHEMBL20164083 | 0.82 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL20164081 | 0.81 | GPR6 (0.41) | CES2CES1GPR6 | |
| SCHEMBL18249606 | 0.77 | HDAC1 (0.45) | GPR6 | |
| SCHEMBL20511997 | 0.77 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL20511998 | 0.77 | CA1 (0.30) | — | |
| SCHEMBL28613923 | 0.77 | GPR6 (0.46) | CES2CES1GPR6 | |
| SCHEMBL28829714 | 0.74 | GPR6 (0.46) | GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107646031-B | Azetidine derivatives as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3297987-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-01-31 | — | — | US | disclosed |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC18A1, SLC18A3 | CES2 233/4885CES1 2329/4885GPR6 846/4885 |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A3 | CES2 166/4885CES1 2533/4885GPR6 1153/4885 |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | CES2 161/4885CES1 2089/4885GPR6 991/4885 |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC6A2, SLC18A3 | CES2 254/4885CES1 2957/4885GPR6 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.